Lersivirine (BioDeep_00000180427)

   

human metabolite blood metabolite


代谢物信息卡片


5-((3,5-Diethyl-1-(2-hydroxyethyl)(3,5-14c2)-1H-pyrazol-4-yl)oxy)benzene-1,3-dicarbonitrile

化学式: C17H18N4O2 (310.1429688)
中文名称: Lersivirine
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC1=C(C(=NN1CCO)CC)OC2=CC(=CC(=C2)C#N)C#N
InChI: InChI=1S/C17H18N4O2/c1-3-15-17(16(4-2)21(20-15)5-6-22)23-14-8-12(10-18)7-13(9-14)11-19/h7-9,22H,3-6H2,1-2H3

描述信息

C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor
C254 - Anti-Infective Agent > C281 - Antiviral Agent

同义名列表

4 个代谢物同义名

5-((3,5-Diethyl-1-(2-hydroxyethyl)(3,5-14c2)-1H-pyrazol-4-yl)oxy)benzene-1,3-dicarbonitrile; 5-{[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile; 5-{[3,5-diethyl-1-(2-hydroxyethyl)pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile; Lersivirine



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Prashant R Nambiar, Daniel Morton, Leland Wayne Dochterman, Christopher Houle, Peter J Thomford, Gwendolyn Fate, Steven A Bailey, Gregory L Finch. Two-year carcinogenicity study in rats with a nonnucleoside reverse transcriptase inhibitor. Toxicologic pathology. 2015 Apr; 43(3):354-65. doi: 10.1177/0192623314544381. [PMID: 25122632]
  • Christopher D Houle, Gregory L Finch, Robert J Mauthe, David M Potter, Jacqueline A Walisser, Iain B Gardner, Robert H DeWit. Effects of lersivirine on canine and rodent thyroid function. Toxicologic pathology. 2014 Jul; 42(5):897-912. doi: 10.1177/0192623313503516. [PMID: 24135463]
  • Pietro Vernazza, Cunshan Wang, Anton Pozniak, Elizabeth Weil, Piotr Pulik, David A Cooper, Richard Kaplan, Adriano Lazzarin, Hernan Valdez, James Goodrich, Julie Mori, Charles Craig, Margaret Tawadrous. Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial. Journal of acquired immune deficiency syndromes (1999). 2013 Feb; 62(2):171-9. doi: 10.1097/qai.0b013e31827a2ba2.. [PMID: 23328090]
  • John Davis, Grant Langdon, Gary Layton, Chew Lan Chong, Marie-Noella Ndongo, Manoli Vourvahis. The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects. European journal of clinical pharmacology. 2012 Nov; 68(11):1567-72. doi: 10.1007/s00228-012-1287-5. [PMID: 22527351]
  • Manoli Vourvahis, John Davis, Rong Wang, Gary Layton, Heng Wee Choo, Chew-Lan Chong, Margaret Tawadrous. Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects. Antimicrobial agents and chemotherapy. 2012 Aug; 56(8):4303-9. doi: 10.1128/aac.06282-11. [PMID: 22644026]
  • Grant Langdon, John Davis, Gary Layton, Chew-Lan Chong, Georges Weissgerber, Manoli Vourvahis. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects. British journal of clinical pharmacology. 2012 May; 73(5):768-75. doi: 10.1111/j.1365-2125.2011.04136.x. [PMID: 22040521]
  • Manoli Vourvahis, Grant Langdon, Gary Layton, Robert R Labadie, Heng Wee Choo, Marie-Noella Ndongo, John Davis. The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects. Journal of acquired immune deficiency syndromes (1999). 2012 May; 60(1):24-32. doi: 10.1097/qai.0b013e31824c4186. [PMID: 22517413]
  • Manoli Vourvahis, Grant Langdon, Robert R Labadie, Gary Layton, Marie-Noella Ndongo, Subhashis Banerjee, John Davis. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects. Antimicrobial agents and chemotherapy. 2012 Feb; 56(2):887-92. doi: 10.1128/aac.00572-11. [PMID: 22123705]
  • John Davis, Frances Hackman, Marie-Noella Ndongo, HengWee Choo, Drew Lewis, Margaret Tawadrous, James Goodrich, Grant Langdon. Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clinical therapeutics. 2010 Oct; 32(11):1889-95. doi: 10.1016/j.clinthera.2010.10.007. [PMID: 21095483]
  • Manoli Vourvahis, Michelle Gleave, Angus N R Nedderman, Ruth Hyland, Iain Gardner, Martin Howard, Sarah Kempshall, Claire Collins, Robert LaBadie. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers. Drug metabolism and disposition: the biological fate of chemicals. 2010 May; 38(5):789-800. doi: 10.1124/dmd.109.031252. [PMID: 20124396]
  • Gerd Fätkenheuer, Schlomo Staszewski, Andreas Plettenburg, Frances Hackman, Gary Layton, Lynn McFadyen, John Davis, Tim M Jenkins. Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients. AIDS (London, England). 2009 Oct; 23(16):2115-22. doi: 10.1097/qad.0b013e32832fef5b. [PMID: 19779321]
  • D K Walker, J Davis, C Houle, I B Gardner, R Webster. Species differences in the multiple-dose pharmacokinetics of the non-nucleoside reverse transcriptase inhibitor (NNRTI) UK-453,061 in animals and man: implications for safety considerations. Xenobiotica; the fate of foreign compounds in biological systems. 2009 Jul; 39(7):534-43. doi: 10.1080/00498250902903079. [PMID: 19480560]